logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Cystic Fibrosis Market, By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators), By Mode of Administration (Oral, Inhaled) opportunities and forecast 2020-2027

  • DLR2158
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Growing prevalence of the Cystic Fibrosis (CF) coupled with the increasing treatment rate is one of key factors expected to propel demand for the CF therapeutics over forecast period. Moreover, surge in R&D funding by private and public organizations, increasing number of the initiatives undertaken by various non-profit organizations, and the presence of favourable reimbursement policies are few of the crucial reasons expected to drive market in the coming years.

As per the data published by the Cystic Fibrosis Foundation (CFF), the incidence of such hereditary disorders is continuously growing. In the U.S., 2015, there were almost 28,983 patients as compared to 26,366 patients in the year 2010. Swelling year-on-year growth in number of patient results in surging demand for the effective and efficient CF therapeutics. Few of the commercially obtainable accepted drug class are CF Transmembrane Conductance Regulator (CFTR) modulators, bronchodilators, mucolytic, anti-infective, antibiotics (oral, inhaled, or parental feeding formulae), anti-inflammatory drugs, and various pancreatic enzyme supplements.

Segment Overview

Based on drug class, the market is characterized into mucolytics, pancreatic enzyme supplements, bronchodilators, and the CFTR modulators. The main consideration in treatment of the CF is maintaining lung function while controlling the respiratory infection and also clearing airways of the mucus, managing nutritional therapy, and regulating the complications.
Rising number of the drug compositions in pipeline of key players is one of pivotal factors likely to impel the market growth. Furthermore, increasing number of the clinical trials to increase its target patient base with existing drug portfolio is amongst some of drivers for the market. Rising R&D activities are anticipated to driving the market growth. Some of pipelined drugs are (VX-445 + tezacaftor + ivacaftor); AZD-5634; PTI-428; QR-010; and POL-6014.

Regional Overview

North America accounted for largest revenue in 2019. CF is the most prevalent in the region as most of people affected are of Caucasian descent. Additionally, initiatives taken by the CF Foundation and the Cystic Fibrosis Canada are one of key reasons accounted for the largest share.
Though, Asia Pacific is likely to be the fastest rising segment with the profitable growth rate. Although the occurrence of the CF is less recurrently reported in Asia Pacific region due to the underdiagnoses and also lack of country-specific patient registries, increasing awareness about the disorders and treatment options is anticipated to boost the segment over forecast period. Economic development in the region and enhancing healthcare facilities are anticipated to boost market during the forecast period.

Competitor overview

The key players in the market are constantly involved in development of new or the combination of products to treat the disorders. Investment in R&D is one of strategic measures to beat competition. The presence of numerous non-profit organizations such as the Cystic Fibrosis Worldwide, Cystic Fibrosis Canada, Cystic Fibrosis Foundation, South African Cystic Fibrosis Trust, and the South African Cystic Fibrosis Association, are steadily involved in activities related to the CF is also one of essential factors accounted for the surging demand. The organizations are capitalising huge amount of the funds to find numerous therapeutics for the CF and to support R&D activities by the key players.

Key Players
  1. AbbVie, Inc.;
  2. F. Hoffmann-La Roche Ltd.;
  3. Gilead;
  4. Novartis AG;
  5. Vertex Pharmaceuticals Inc.;
  6. AIT (Advanced Inhalation Therapies);
  7. Alaxia;
  8. Teva Pharmaceutical Industries Ltd.;
  9. Merck & Co., Inc.;
  10. Alcresta Therapeutics, Inc.;
  11. Allergan;
  12. AstraZeneca.

Market Segmentation
By Drug Class
  • CFTR modulators
  • Pancreatic enzyme supplements
  • Mucolytics
  • Bronchodilators
By Route of Administration
  • Oral
  • Inhaled
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Introduction 8

  • 1.1 Definition 8
  • 1.2 Scope of Study 8
  • 1.3 Research Objective 8
  • 1.4 Assumptions & Limitations 9
    • 1.4.1 Assumptions 9
    • 1.4.2 Limitations 9
  • 1.5 Market Structure 9

2 Research Methodology 10

  • 2.1 Research Process 10
  • 2.2 Primary Research 11
  • 2.3 Secondary Research 11

3 Market Dynamics 12

  • 3.1 Drivers 12
    • 3.1.1 Introduction 12
    • 3.1.2 Development of New Drugs and Therapies 12
    • 3.1.3 Financial Support from CFF in Research and Development of CF Drugs. 12
  • 3.2 Restraints 13
    • 3.2.1 Introduction 13
    • 3.2.2 High Cost of the Drugs and Treatment 13
  • 3.3 Opportunities 13
  • 3.4 Challenges 14
    • 3.4.1 Awareness About the Rare Disease in the Developing Countries 14

4 Market Factor Analysis 15

  • 4.1 Porter’s Five Forces Model 15
    • 4.1.1 Bargaining Power of Suppliers 15
    • 4.1.2 Bargaining Power of Buyers 15
    • 4.1.3 Threat of New Entrants 16
    • 4.1.4 Threat of Substitutes 16
    • 4.1.5 Intensity of Rivalry 16

5 Cystic Fibrosis Market, By Treatment Method 17

  • 5.1 Introduction 17
  • 5.2 Medication 18
  • 5.3 Devices 19
  • 5.4 Other Treatments 20

6 Cystic Fibrosis Market, By Regions 22

  • 6.1 Introduction 22
  • 6.2 North America 24
  • 6.3 Europe 27
  • 6.4 Asia-Pacific 33
  • 6.5 Middle East & Africa 38

7 Company Share Analysis 41

    8 Company Profile 43

    • 8.1 AbbVie 43
      • 8.1.1 Company Overview 43
      • 8.1.2 Product Overview 43
      • 8.1.3 Financials 44
      • 8.1.4 Key Developments Error! Bookmark not defined.
    • 8.2 Allergan Plc 46
      • 8.2.1 Company Overview 46
      • 8.2.2 Product Overview 46
      • 8.2.3 Financials 46
      • 8.2.4 Key Developments Error! Bookmark not defined.
    • 8.3 Chiesi Farmaceutici S.p.A. 48
      • 8.3.1 Company Overview 48
      • 8.3.2 Product/Business Segment Overview 48
      • 8.3.3 Financials 48
      • 8.3.4 Key Developments 49
    • 8.4 F. Hoffmann-La Roche AG 50
      • 8.4.1 Company Overview 50
      • 8.4.2 Product/Business Segment Overview 50
      • 8.4.3 Financials 50
      • 8.4.4 Key Developments 51
    • 8.5 Gilead Sciences 52
      • 8.5.1 Company Overview 52
      • 8.5.2 Product Overview 52
      • 8.5.3 Financials 52
      • 8.5.4 Key Developments 52
    • 8.6 Novartis AG 53
      • 8.6.1 Company Overview 53
      • 8.6.2 Product Overview 53
      • 8.6.3 Financials 53
      • 8.6.4 Key Developments 54
    • 8.7 Pharmaxis Ltd. 55
      • 8.7.1 Company Overview 55
      • 8.7.2 Product Overview 55
      • 8.7.3 Financials 55
      • 8.7.4 Key Developments 56
    • 8.8 PTC Therapeutics 57
      • 8.8.1 Company Overview 57
      • 8.8.2 Product Overview 57
      • 8.8.3 Financials 57
      • 8.8.4 Key Developments 58
    • 8.9 Vertex Pharmaceuticals Incorporated 59
      • 8.9.1 Company Overview 59
      • 8.9.2 Product/Business Segment Overview 59
      • 8.9.3 Financials 59

    Report You Might be Interested